Kowa Company, Ltd. v. Hetero Drugs Limited
1:17-cv-00762
Overview
Parties
Defendant
Hetero Labs Limited Unit-V NPE (University / Research)
Represented By
0 Attorneys ListedHetero Drugs Limited NPE (University / Research)
Represented By
0 Attorneys ListedPlaintiff
Kowa Company, Ltd. Operating Company
Represented By
2 Attorneys ListedBarnard, Mezzanotte, Pinnie, Seelaus & Kraft, LLP
1205 N. Orange Street, Wilmington, DE 19801
DLA Piper LLP
1201 N. Market Street, Suite 2100, Wilmington, DE 19801
Counter Claimant
Hetero Labs Limited NPE (University / Research)
Represented By
0 Attorneys ListedCounter Defendant
Nissan Chemical Industries, Ltd. Operating Company
Represented By
2 Attorneys ListedBarnard, Mezzanotte, Pinnie, Seelaus & Kraft, LLP
1205 N. Orange Street, Wilmington, DE 19801
DLA Piper LLP
1201 N. Market Street, Suite 2100, Wilmington, DE 19801
Kowa Pharmaceuticals America, Inc. Operating Company
Represented By
2 Attorneys ListedBarnard, Mezzanotte, Pinnie, Seelaus & Kraft, LLP
1205 N. Orange Street, Wilmington, DE 19801
DLA Piper LLP
1201 N. Market Street, Suite 2100, Wilmington, DE 19801
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 17 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πͺπΊ European Patent Office (UPC States) | European Counterpart (EP) | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| π PCT International (WIPO) | PCT World Application | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US8557993
Crystalline forms of pitavastatin calcium
|
Filed: 2012-10-31
Issued: 2013-10-15
|
Active (5.9 yrs remaining)
Expires: 2032-10-31
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term; injunctive relief viable.
Standard Statutory Term β No obviousness-type double patenting noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).